{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:21:21Z","timestamp":1772202081197,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["NRF-2019R1A2C1004582"],"award-info":[{"award-number":["NRF-2019R1A2C1004582"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12272-023-01462-1","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:01:46Z","timestamp":1695200506000},"page":"713-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone"],"prefix":"10.1007","volume":"46","author":[{"given":"Ji-Young","family":"Byeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang\u2011Keun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pureum","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon-Gon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-1981","authenticated-orcid":false,"given":"Seok-Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"2","key":"1462_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5414\/cpp45110","volume":"45","author":"JW Bae","year":"2007","unstructured":"Bae JW, Kim MJ, Park YS, Myung CS, Jang CG, Lee SY (2007) Considerable interindividual variation in the pharmacokinetics of tolperisone HCl. Int J Clin Pharmacol Ther 45(2):110\u2013113. https:\/\/doi.org\/10.5414\/cpp45110","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"1462_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12272-009-1232-z","volume":"32","author":"JW Bae","year":"2009","unstructured":"Bae JW, Kim JH, Choi CI, Kim MJ, Kim HJ, Byun SA, Chang YS, Jang CG, Park YS, Lee SY (2009) Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch Pharm Res 32(2):269\u2013273. https:\/\/doi.org\/10.1007\/s12272-009-1232-z","journal-title":"Arch Pharm Res"},{"issue":"4","key":"1462_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2125.2010.03853.x","volume":"71","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Jang CG, Lee SY (2011) Effects of CYP2C9*1\/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71(4):550\u2013555. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03853.x","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1462_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5414\/cp201467","volume":"50","author":"JW Bae","year":"2012","unstructured":"Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY (2012) Effects of CYP2C9*1\/*3 and *1\/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. Int J Clin Pharmacol Ther 50(9):683\u2013689. https:\/\/doi.org\/10.5414\/cp201467","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1462_CR5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12272-020-01293-4","volume":"43","author":"JW Bae","year":"2020","unstructured":"Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207\u20131213. https:\/\/doi.org\/10.1007\/s12272-020-01293-4","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1462_CR6","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/clpt.2012.188","volume":"93","author":"J Byeon","year":"2013","unstructured":"Byeon J, Lee H, Choi C, Jang C, Bae J, Lee S (2013a) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of tolperisone in Koreans. Clin Pharmacol Ther 93(1):S24","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clinthera.2013.07.147","volume":"35","author":"JY Byeon","year":"2013","unstructured":"Byeon JY, Lee JY, Jeon JS, Lee JE, Kim SH, Bae JW, Jang CG, Lee SY (2013b) Pharmacokinetics of tolperisone in relation to CYP2C19 genotypes. Clin Ther 35(8):e54. https:\/\/doi.org\/10.1016\/j.clinthera.2013.07.147","journal-title":"Clin Ther"},{"issue":"9","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s12272-018-1075-6","volume":"41","author":"JY Byeon","year":"2018","unstructured":"Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41(9):921\u2013930. https:\/\/doi.org\/10.1007\/s12272-018-1075-6","journal-title":"Arch Pharm Res"},{"issue":"11","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12272-021-01357-z","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037\u20131049. https:\/\/doi.org\/10.1007\/s12272-021-01357-z","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1462_CR10","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12272-021-01361-3","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076\u20131090. https:\/\/doi.org\/10.1007\/s12272-021-01361-3","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1462_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12272-022-01388-0","volume":"45","author":"CK Cho","year":"2022","unstructured":"Cho CK, Kang P, Park HJ, Ko E, Mu CY, Lee YJ, Choi CI, Kim HS, Jang CG, Bae JW, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Arch Pharm Res 45(5):352\u2013366. https:\/\/doi.org\/10.1007\/s12272-022-01388-0","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1462_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12272-022-01423-0","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park HJ, Ko E, Mu CY, Jang CG, Lee SY, Lee YJ (2023a) Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects. Arch Pharm Res 46(2):111\u2013116. https:\/\/doi.org\/10.1007\/s12272-022-01423-0","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1462_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12272-022-01422-1","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park JI, Jang CG, Lee SY, Choi CI, Bae JW, Lee YJ (2023b) Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone. Arch Pharm Res 46(1):59\u201364. https:\/\/doi.org\/10.1007\/s12272-022-01422-1","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1462_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1177\/0091270011432168","volume":"52","author":"CI Choi","year":"2012","unstructured":"Choi CI, Bae JW, Jang CG, Lee SY (2012a) Tamsulosin exposure is significantly increased by the CYP2D6*10\/*10 genotype. J Clin Pharmacol 52(12):1934\u20131938. https:\/\/doi.org\/10.1177\/0091270011432168","journal-title":"J Clin Pharmacol"},{"key":"1462_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchromb.2012.10.027","volume":"911","author":"CI Choi","year":"2012","unstructured":"Choi CI, Park JI, Lee HI, Lee YJ, Jang CG, Bae JW, Lee SY (2012b) Determination of tolperisone in human plasma by liquid chromatography\/tandem mass spectrometry for clinical application. J Chromatogr B Analyt Technol Biomed Life Sci 911:59\u201363. https:\/\/doi.org\/10.1016\/j.jchromb.2012.10.027","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"1462_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/JCP.0b013e3182a608a2","volume":"34","author":"CI Choi","year":"2014","unstructured":"Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY (2014) Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol 34(1):139\u2013142. https:\/\/doi.org\/10.1097\/JCP.0b013e3182a608a2","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1462_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1124\/dmd.31.5.631","volume":"31","author":"B Dalmadi","year":"2003","unstructured":"Dalmadi B, Leibinger J, Szeber\u00e9nyi S, Borb\u00e1s T, Farkas S, Szombathelyi Z, Tihanyi K (2003) Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos 31(5):631\u2013636. https:\/\/doi.org\/10.1124\/dmd.31.5.631","journal-title":"Drug Metab Dispos"},{"key":"1462_CR18","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994a) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419\u201315422","journal-title":"J Biol Chem"},{"key":"1462_CR19","first-page":"594","volume":"46","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994b) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594\u2013598","journal-title":"Mol Pharmacol"},{"issue":"2","key":"1462_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","volume":"76","author":"MS Faber","year":"2004","unstructured":"Faber MS, Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76(2):178\u2013184. https:\/\/doi.org\/10.1016\/j.clpt.2004.04.003","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1462_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5(1):6\u201313. https:\/\/doi.org\/10.1038\/sj.tpj.6500285","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"1462_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00008571-199608000-00008","volume":"6","author":"I Johansson","year":"1996","unstructured":"Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6(4):351\u2013355. https:\/\/doi.org\/10.1097\/00008571-199608000-00008","journal-title":"Pharmacogenetics"},{"issue":"12","key":"1462_CR23","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s12272-021-01363-1","volume":"44","author":"EH Jung","year":"2021","unstructured":"Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109\u20131119. https:\/\/doi.org\/10.1007\/s12272-021-01363-1","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1462_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.1991.8","volume":"49","author":"W Kalow","year":"1991","unstructured":"Kalow W, Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49(1):44\u201348. https:\/\/doi.org\/10.1038\/clpt.1991.8","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1462_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12272-023-01448-z","volume":"46","author":"P Kang","year":"2023","unstructured":"Kang P, Cho CK, Jang CG, Lee SY, Lee YJ, Choi CI, Bae JW (2023) Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects. Arch Pharm Res 46(5):438\u2013447. https:\/\/doi.org\/10.1007\/s12272-023-01448-z","journal-title":"Arch Pharm Res"},{"issue":"7","key":"1462_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-021-01346-2","volume":"44","author":"YH Kim","year":"2021","unstructured":"Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713\u2013724. https:\/\/doi.org\/10.1007\/s12272-021-01346-2","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1462_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12272-021-01366-y","volume":"45","author":"NT Kim","year":"2022","unstructured":"Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 45(2):114\u2013121. https:\/\/doi.org\/10.1007\/s12272-021-01366-y","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1462_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1124\/jpet.105.089805","volume":"315","author":"P Kocsis","year":"2005","unstructured":"Kocsis P, Farkas S, Fodor L, Bielik N, Th\u00e1n M, Kolok S, Gere A, Csejtei M, Tarnawa I (2005) Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther 315(3):1237\u20131246. https:\/\/doi.org\/10.1124\/jpet.105.089805","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1462_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12272-022-01394-2","volume":"45","author":"CM Lee","year":"2022","unstructured":"Lee CM, Kang P, Cho CK, Park HJ, Lee YJ, Bae JW, Choi CI, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Arch Pharm Res 45(6):433\u2013445. https:\/\/doi.org\/10.1007\/s12272-022-01394-2","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1462_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0378-1119(98)00567-8","volume":"226","author":"E Lundqvist","year":"1999","unstructured":"Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226(2):327\u2013338. https:\/\/doi.org\/10.1016\/s0378-1119(98)00567-8","journal-title":"Gene"},{"issue":"9","key":"1462_CR31","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.xphs.2017.04.035","volume":"106","author":"N Marsousi","year":"2017","unstructured":"Marsousi N, Desmeules JA, Rudaz S, Daali Y (2017) Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci 106(9):2380\u20132391. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.035","journal-title":"J Pharm Sci"},{"issue":"5","key":"1462_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/15563650.2015.1022896","volume":"53","author":"V Martos","year":"2015","unstructured":"Martos V, Hofer KE, Rauber-L\u00fcthy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A (2015) Acute toxicity profile of tolperisone in overdose: observational poison centre-based study. Clin Toxicol (phila) 53(5):470\u2013476. https:\/\/doi.org\/10.3109\/15563650.2015.1022896","journal-title":"Clin Toxicol (phila)"},{"issue":"6","key":"1462_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1067\/mcp.2001.120675","volume":"70","author":"R Mendoza","year":"2001","unstructured":"Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM (2001) CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 70(6):552\u2013560. https:\/\/doi.org\/10.1067\/mcp.2001.120675","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1462_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0731-7085(87)80082-1","volume":"5","author":"P Miskolczi","year":"1987","unstructured":"Miskolczi P, Vereczkey L, Frenkl R (1987) Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies. J Pharm Biomed Anal 5(7):695\u2013700. https:\/\/doi.org\/10.1016\/0731-7085(87)80082-1","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"1462_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00228-015-1856-5","volume":"71","author":"M Pawlowska","year":"2015","unstructured":"Pawlowska M, Bogiel M, Duda J, Sieradzki E (2015) Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers. Eur J Clin Pharmacol 71(6):699\u2013705. https:\/\/doi.org\/10.1007\/s00228-015-1856-5","journal-title":"Eur J Clin Pharmacol"},{"key":"1462_CR36","first-page":"369","volume":"133","author":"C Ribi","year":"2003","unstructured":"Ribi C, Vermeulen C, Hauser C (2003) Anaphylactic reactions to tolperisone (Mydocalm). Swiss Med Wkly 133:369\u2013371","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"1462_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113. https:\/\/doi.org\/10.1016\/j.clpt.2005.10.002","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1462_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genom 17(2):93\u2013101. https:\/\/doi.org\/10.1097\/01.fpc.0000239974.69464.f2","journal-title":"Pharmacogenet Genom"},{"issue":"2","key":"1462_CR39","first-page":"131","volume":"9","author":"I Tantcheva-Po\u00f3r","year":"1999","unstructured":"Tantcheva-Po\u00f3r I, Zaigler M, Rietbrock S, Fuhr U (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9(2):131\u2013144","journal-title":"Pharmacogenetics"},{"key":"1462_CR40","first-page":"127","volume":"58","author":"A Vora","year":"2010","unstructured":"Vora A (2010) Tolperisone. J Assoc Phys India 58:127\u2013128","journal-title":"J Assoc Phys India"},{"issue":"8","key":"1462_CR41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s12272-022-01403-4","volume":"45","author":"SS Whang","year":"2022","unstructured":"Whang SS, Cho CK, Jung EH, Kang P, Park HJ, Lee YJ, Choi CI, Bae JW, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Arch Pharm Res 45(8):584\u2013595. https:\/\/doi.org\/10.1007\/s12272-022-01403-4","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1462_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/gtmb.2011.0084","volume":"16","author":"LJ Zuo","year":"2012","unstructured":"Zuo LJ, Guo T, Xia DY, Jia LH (2012) Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomark 16(2):102\u2013108. https:\/\/doi.org\/10.1089\/gtmb.2011.0084","journal-title":"Genet Test Mol Biomark"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01462-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-023-01462-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01462-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:09:19Z","timestamp":1696482559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-023-01462-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1007\/s12272-023-01462-1","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}